CTLA4 and melanoma: Particularly, the triple combination of anti-PD-L1, anti-CTLA-4 and CSC-DC vaccine significantly eliminated ALDHhigh CSCs, which was accompanied by improved T cell expansion, suppressed TGF-β release, increased IFN-γ, and promoted CD8+ T cell response against melanoma CSCs [324].